Investment bank Canaccord Genuity downgraded Quanterix shares from Buy to Hold, lowering the price target to $5 following disappointing Q2 2025 revenues and uncertainties in the integration of Akoya Biosciences. The company reported a 29% revenue decline year-over-year due to softness in academic and pharmaceutical sectors. Concerns were raised about leadership departures at Akoya and the risk to synergy realization, putting 2026 breakeven cash flow targets in doubt. Despite long-term potential in Alzheimer’s diagnostics, valuation expansion appears constrained without consistent execution.